Elutia vs Lineage Cell Therapeutics
ELUT and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELUT and LCTX compare
Lineage Cell Therapeutics is the larger company, worth 5.5 times as much as Elutia ($201M against $36.4M).
Lineage Cell Therapeutics grew revenue faster over the last twelve months (19.9% versus −0.34% for Elutia).
Elutia keeps more of each dollar of sales as profit, with a net margin of 427% compared with −247% at Lineage Cell Therapeutics.
Elutia scores higher on the StockData Score (9 against 8 for Lineage Cell Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELUT | LCTX |
|---|---|---|
| Size and price | ||
| Market cap | $36.4M | $201M |
| Share price | $0.823 | $0.795 |
| Change, 1 year | 10.8% | −55.8% |
| Change, 5 years | −84.2% | −60.0% |
| Beta (5Y) | 0.43 | 1.21 |
| Employees | 26 | 77 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.0× (better) | 15.4× |
| P/B | 2.3× (better) | 3.3× |
| FCF yield | −126% | −12.1% (better) |
| Fair value | $0.923 | $0.657 |
| Margin of safety | 10.8% (better) | −21.0% |
| Growth | ||
| Revenue growth (TTM) | −0.34% | 19.9% (better) |
| Revenue growth, 5Y average | −22.0% | 51.5% (better) |
| Profitability | ||
| Gross margin | 57.8% | – |
| Operating margin | −215% | −205% (better) |
| Net margin | 427% (better) | −247% |
| FCF margin | −379% | −186% (better) |
| Return on equity | – | −59.0% |
| Return on invested capital | – | −262% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.77 | 6.61 (better) |
| Altman Z-score | −6.60 | −3.80 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.8% | 46.1% |
| Held by insiders | 52.0% | 74.4% |
| Insider net buying, 12 months | $212K (better) | $24.4K |
| Short interest, % of float | 0.16% | 37.7% |
Go deeper
- ELUT stock overview
- ELUT income statement
- ELUT valuation and score
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.